Themis Medicare Limited returned to profitability on a consolidated basis in FY26, reporting a net profit of ₹1.14 crore compared to ₹29.83 crore in the previous year. The company's consolidated revenue from operations stood at ₹342.24 crore, a decrease from ₹405.51 crore in FY25. The Board of Directors, at its meeting held on May 28, 2026, approved the audited standalone and consolidated financial results for the year ended March 31, 2026, reviewed by the Audit Committee and accompanied by the report of Statutory Auditors M/s. Krishaan & Co., Chartered Accountants. The Board also recommended a final dividend of Re. 0.50 per equity share (face value Re. 1 each), aggregating to ₹4,60,50,060, subject to shareholder approval at the forthcoming Annual General Meeting.

Q4 FY26 Performance: Sharp Turnaround

For the quarter ended March 31, 2026 (Q4 FY26), Themis Medicare reported a consolidated net profit of ₹8.89 crore, a significant turnaround from a loss of ₹9.66 crore in the corresponding period of the previous year. Revenue for the quarter rose 6.7% year-on-year to ₹76.53 crore. EBITDA for the quarter turned positive at ₹3.76 crore against a loss of ₹5.78 crore in Q4 FY25, reflecting improved operational efficiencies and cost rationalization. The Hospital segment emerged as a major growth driver during the year, contributing 50% of total revenue.

Consolidated Financial Highlights (Q4 FY26)

The table below summarizes the consolidated quarterly performance:

Consolidated Financial Highlights (FY26)

The full-year consolidated performance is presented below:

Standalone Financial Results

On a standalone basis, the company reported a net loss of ₹1,418.55 lakhs for the year ended March 31, 2026, compared to a net profit of ₹2,392.15 lakhs in the previous year. Standalone revenue from operations for FY26 stood at ₹34,223.55 lakhs versus ₹40,551.16 lakhs in FY25. For Q4 FY26, standalone revenue from operations was ₹7,653.05 lakhs against ₹7,170.16 lakhs in Q4 FY25, with a net profit of ₹196.56 lakhs compared to a net loss of ₹774.48 lakhs in the year-ago quarter. Basic and diluted EPS on a standalone basis for FY26 stood at ₹(1.54) each, against ₹2.60 (basic) and ₹2.59 (diluted) in FY25.

The standalone results include two exceptional items: an impact of ₹86.53 lakhs related to the four Labour Codes notified by the Government of India on November 21, 2025, and a provision of ₹129.39 lakhs for investments and receivables in M/s. Carpo Medicals Limited (UK), a wholly owned subsidiary that was struck off effective April 14, 2025, pending RBI approval under FEMA for write-off.

Standalone Statement of Assets and Liabilities

Key balance sheet items on a standalone basis are presented below:

Consolidated Statement of Assets and Liabilities

Key consolidated balance sheet items are as follows:

Corporate Governance and Auditor Appointments

The Board re-appointed M/s. R. Nanabhoy & Co., Cost Accountants (FRN - 000011), a firm established in 1948 by Late Shri. Ruttonshaw Nanabhoy, as Cost Auditor for the financial year 2026-27. The statutory auditors, M/s. Krishaan & Co., Chartered Accountants, issued an unmodified audit opinion on both the standalone and consolidated financial results, with no audit qualifications or reservations. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013. Dr. Sachin Patel, Managing Director & CEO, attributed the recovery to ongoing cost rationalization, improved business productivity, and better operational efficiency.

Themis Medicare Limited has filed a disclosure with BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in connection with its proposed preferential allotment of convertible warrants. The disclosure was made on 12th May, 2026, and was signed by Dr. Dinesh Patel, Chairman (DIN: 00033273).

Background and Regulatory Context

The process for the preferential allotment of convertible warrants was initiated following approval by the Board of Directors at its meeting held on 13th February, 2026. Subsequent to the board approval, the company had submitted an application to both BSE Limited and the National Stock Exchange of India Limited seeking in-principle approval for the preferential allotment.

Following the submission of the application, the stock exchanges raised certain queries and observations. In response, and in compliance with the provisions of the Articles of Association of the Company, Themis Medicare took the necessary steps to address these regulatory requirements.

Documents Submitted

The company obtained and submitted two key documents as part of its compliance obligations. The following table summarises the documents filed:

Both documents have been duly updated and hosted on the official website of the company at www.themismedicare.com . The Valuation Report and the revised Compliance Certificate are accessible through the statutory documents section of the website.

Compliance and Disclosure

The disclosure has been made in strict compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Themis Medicare has requested both exchanges to take the intimation on record. The company's registered office is located at Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi, Gujarat, and its corporate office is situated at 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104.